NEW TREATMENT OPTIONS UNDER INVESTIGATION FOR PELVIC ORGAN PROLAPSE Design of next generation meshes using degradable polymers and stem cell based surgical constructs
Pelvic organ prolapse (POP) develops when tissues, pelvic floor muscles and ligaments that support the pelvic organs (bladder, uterus and bowel) are damaged, usually in childbirth. This injury causes the organs to shift, or ‘drop’, into the vagina or event outside of the body. This can lead to debilitating symptoms including poor bladder or bowel control and pain during sex
POP Facts
- 1 in 4 women globally in their 40s live with POP
- 1 in 2 women over 50 years of age live with POP
- $200 million annual cost to the Australian healthcare system
POP is a lifelong, potentially debilitating condition. Despite the high prevalence, there is no cure for POP.
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
Dr Shayanti Mukherjee specialises in innovative cell-based therapies for pelvic floor disorders and birth trauma injuries.
Dr Mukherjee’s research uses a woman’s own stem cells to create a 3D-printed degradable mesh, promising to avoid the complications that have plagued previous synthetic non-degradable meshes.
“By integrating cutting-edge techniques like electrospinning and 3D printing of materials and cells, I aim to revolutionise maternal urogynaecological health, offering transformative solutions and improving the wellbeing of women affected by this prevalent issue.”
“This research has the potential to revolutionise therapies for pelvic floor regeneration and enable personalised medicine for women,” she said.
“By advancing innovative cell-based therapies, we are on the brink of transforming the landscape of maternal urogynaecological health, promising a brighter and healthier future for women across the globe,” said Dr Mukherjee.
Source: Hudson Institute of Medical Research
-
Changes in MBS bulk billing incentives address GP capacity in women’s health
Dr. Sneha Wadhwani, a General Practitioner in Bondi, and Conjoint Lecturer at UNSW School of Medicine, is actively involved in enhancing women’s health services across Australia. As the Co-founder and Clinical Director of Evoca Women’s Health, she highlights the significant improvements in funding for women’s health, particularly with the new MBS bulk billing incentives, in new codes, that commenced on November 1, 2025.
-
Artificial Intelligence (AI) & data skilling clinicians
In this first release, world renowned AI and medical data science experts Dr Anthony Chang and Professor Enrico Coiera spoke to Australian Health Journal reporter Anne Dao at AIMed 2019 Sydney. The conference aimed at clinicians and non-clinicians discussed current clinical applications of Artificial Intelligence in medical imaging, decision support, use of predictive healthcare and machine learning.
-
Belonging in a medical device company
Edith de Boer is the HR Director for Zimmer Biomet in Australia and New Zealand. Her career originally was in telecommunications and consulting in Europe. After leaving The Netherlands, Edith worked into the Australian medical research industry, before moving into a human resources role at Zimmer Biomet. Edith spoke to Australian Health Journal about her role and the organisation.
